drug · small molecule
CARIPRAZINE HYDROCHLORIDE
Marketedupdated 5mo agoby $ABBV AbbVie Inc.🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 4Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for 3 indications.
indications
investigational
SchizophreniaMajor Depression
targets
D(2) dopamine receptorD(3) dopamine receptor
all catalysts(14)
approval · 14
Sep 17, 2015
approval
$ABBV262.82+1.11%
VRAYLAR (CARIPRAZINE HYDROCHLORIDE) — FDA approval
CARIPRAZINE HYDROCHLORIDE
→
Sep 17, 2015
approval
$ABBV262.82+1.11%
VRAYLAR (CARIPRAZINE HYDROCHLORIDE) — FDA approval
CARIPRAZINE HYDROCHLORIDE
→
Feb 23, 2017
approval
$ABBV262.82+1.11%
VRAYLAR (CARIPRAZINE HYDROCHLORIDE) — FDA approval
CARIPRAZINE HYDROCHLORIDE
→
Nov 9, 2017
approval
$ABBV262.82+1.11%
VRAYLAR (CARIPRAZINE HYDROCHLORIDE) — FDA approval
CARIPRAZINE HYDROCHLORIDE
→
Nov 9, 2017
approval
$ABBV262.82+1.11%
VRAYLAR (CARIPRAZINE HYDROCHLORIDE) — FDA approval
CARIPRAZINE HYDROCHLORIDE
→
Nov 28, 2018
approval
$ABBV262.82+1.11%
VRAYLAR (CARIPRAZINE HYDROCHLORIDE) — FDA approval
CARIPRAZINE HYDROCHLORIDE
→
May 24, 2019
approval
$ABBV262.82+1.11%
VRAYLAR (CARIPRAZINE HYDROCHLORIDE) — FDA approval
CARIPRAZINE HYDROCHLORIDE
→
Dec 16, 2022
approval
$ABBV262.82+1.11%
VRAYLAR (CARIPRAZINE HYDROCHLORIDE) — FDA approval
CARIPRAZINE HYDROCHLORIDE
→
Nov 22, 2024
approval
$ABBV262.82+1.11%
VRAYLAR (CARIPRAZINE HYDROCHLORIDE) — FDA approval
CARIPRAZINE HYDROCHLORIDE
→
Dec 16, 2025
approval
CARIPRAZINE HYDROCHLORIDE — FDA approval
CARIPRAZINE HYDROCHLORIDE
→
Dec 18, 2025
approval
$ABBV262.82+1.11%
VRAYLAR (CARIPRAZINE HYDROCHLORIDE) — FDA approval
CARIPRAZINE HYDROCHLORIDE
→
Dec 18, 2025
approval
$ABBV262.82+1.11%
VRAYLAR (CARIPRAZINE HYDROCHLORIDE) — FDA approval
CARIPRAZINE HYDROCHLORIDE
→
Dec 18, 2025
approval
$ABBV262.82+1.11%
VRAYLAR (CARIPRAZINE HYDROCHLORIDE) — FDA approval
CARIPRAZINE HYDROCHLORIDE
→
Dec 18, 2025
approval
$ABBV262.82+1.11%
VRAYLAR (CARIPRAZINE HYDROCHLORIDE) — FDA approval
CARIPRAZINE HYDROCHLORIDE
→
Patent cliff
source: FDA Orange Bookfirst barrier falls
Dec 16, 2028
~2.2 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (50)
- Mar 17, 2030patentUS 7737142*PED3.5y
- Mar 17, 2030patentUS 7737142*PED3.5y
- Mar 17, 2030patentUS 7737142*PED3.5y
- Mar 17, 2030patentUS 7737142*PED3.5y
- Mar 17, 2030patentUS 7737142*PED3.5y
- Mar 17, 2030patentUS 7737142*PED3.5y
- Jan 16, 2030patentUS RE47350*PED3.3y
- Jan 16, 2030patentUS RE47350*PED3.3y
- Jan 16, 2030patentUS RE47350*PED3.3y
- Jan 16, 2030patentUS RE49110*PED3.3y
- Jan 16, 2030patentUS RE49110*PED3.3y
- Jan 16, 2030patentUS RE49110*PED3.3y
- Jan 16, 2030patentUS RE49110*PED3.3y
- Jan 16, 2030patentUS RE49110*PED3.3y
- Jan 16, 2030patentUS RE49110*PED3.3y
- Jan 16, 2030patentUS RE49302*PED3.3y
- Jan 16, 2030patentUS RE49302*PED3.3y
- Jan 16, 2030patentUS RE49302*PED3.3y
- Jan 16, 2030patentUS RE49302*PED3.3y
- Sep 17, 2029compositionUS 77371423.0y
- Sep 17, 2029compositionUS 77371423.0y
- Sep 17, 2029compositionUS 77371423.0y
- Sep 17, 2029compositionUS 77371423.0y
- Sep 17, 2029compositionUS 77371423.0y
- Sep 17, 2029compositionUS 77371423.0y
- Jul 16, 2029method-of-use (U-2545)US RE473502.8y
- Jul 16, 2029method-of-use (U-2544)US RE473502.8y
- Jul 16, 2029method-of-use (U-2545)US RE473502.8y
- Jul 16, 2029method-of-use (U-3503)US RE491102.8y
- Jul 16, 2029method-of-use (U-2545)US RE491102.8y
- Jul 16, 2029method-of-use (U-2543)US RE491102.8y
- Jul 16, 2029method-of-use (U-3503)US RE491102.8y
- Jul 16, 2029method-of-use (U-2544)US RE491102.8y
- Jul 16, 2029method-of-use (U-3503)US RE491102.8y
- Jul 16, 2029method-of-use (U-2545)US RE493022.8y
- Jul 16, 2029method-of-use (U-3503)US RE493022.8y
- Jul 16, 2029method-of-use (U-2545)US RE493022.8y
- Jul 16, 2029method-of-use (U-3503)US RE493022.8y
- Jun 20, 2029patentUS 7943621*PED2.7y
- Jun 20, 2029patentUS 7943621*PED2.7y
- Jun 16, 2029patentUS 7943621*PED2.7y
- Jun 16, 2029patentUS 7943621*PED2.7y
- Jun 16, 2029patentUS 7943621*PED2.7y
- Jun 16, 2029patentUS 7943621*PED2.7y
- Dec 20, 2028compositionUS 79436212.2y
- Dec 20, 2028compositionUS 79436212.2y
- Dec 16, 2028compositionUS 79436212.2y
- Dec 16, 2028compositionUS 79436212.2y
- Dec 16, 2028compositionUS 79436212.2y
- Dec 16, 2028compositionUS 79436212.2y
FDA exclusivities (17)
- Jun 18, 2029PEDPediatric (6mo bonus)2.7y
- Jun 18, 2029PEDPediatric (6mo bonus)2.7y
- Jun 18, 2029PEDPediatric (6mo bonus)2.7y
- Jun 18, 2029PEDPediatric (6mo bonus)2.7y
- Jun 18, 2029PEDPediatric (6mo bonus)2.7y
- Jun 18, 2029PEDPediatric (6mo bonus)2.7y
- Dec 18, 2028NPPNew Product (3y)2.2y
- Dec 18, 2028M-14Method (3y)2.2y
- Dec 18, 2028NPPNew Product (3y)2.2y
- Dec 18, 2028M-14Method (3y)2.2y
- Dec 18, 2028NPPNew Product (3y)2.2y
- Dec 18, 2028M-14Method (3y)2.2y
- Dec 18, 2028NPPNew Product (3y)2.2y
- Dec 18, 2028M-14Method (3y)2.2y
- Dec 18, 2028NPPNew Product (3y)2.2y
- Dec 18, 2028M-14Method (3y)2.2y
- Dec 18, 2028M-14Method (3y)2.2y
News(2)
- As BMS’ Cobenfy struggles to gain traction, MapLight knocks on the doorDespite the recent emergence of a new drug class, schizophrenia remains one of the most challenging neuropsychiatric diseases to treat—and Cobenfy's first steps into the market indicate there is st…biospace · 1mo ago
- AbbVie shares pressured as Q2 I&I beat falls below investor expectationsAbbVie investors’ sky-high expectations led to a 4% share decline on Friday as the company reported more modest consensus beats than expected.biospace · 2mo ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that